On-command drug release from nanochains inhibits growth of breast tumors

Pharmaceutical Research

Volumn 31, Issue 6, 2014, Pages 1460-1468

  Peiris, Pubudu M ^a,b,c   Tam, Morgan ^a,c   Vicente, Peter ^a,c   Abramowski, Aaron ^a,c   Toy, Randall ^a,c   Bauer, Lisa ^c   Mayer, Aaron ^a,c   Pansky, Jenna ^a,c   Doolittle, Elizabeth ^a,c   Tucci, Samantha ^a,c   Schmidt, Erik ^a,c   Shoup, Christopher ^a,c   Rao, Swetha ^a,c   Murray, Kaitlyn ^a,c   Gopalakrishnan, Ramamurthy ^b,c   Keri, Ruth A ^b,c   Basilion, James P ^a,b,c   Griswold, Mark A ^b,c   Karathanasis, Efstathios ^a,b,c  

^a Case Western Reserve University   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

4T1 cells; bioluminescence imaging; chemotherapy; doxorubicin; multicomponent nanoparticle; nanochain; radiofrequency triggered release; triple negative breast cancer

Indexed keywords

DOXORUBICIN; FIREFLY LUCIFERASE; IRON OXIDE; LIPOSOME; NANOCHAIN; NANOPARTICLE; NANOSPHERE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; MACROGOL DERIVATIVE; PHARMACEUTICAL VEHICLES AND ADDITIVES;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE; BREAST CANCER; CANCER INHIBITION; CANCER MODEL; CONTROLLED STUDY; DRUG RELEASE; FEMALE; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOFREQUENCY; SURVIVAL TIME; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; BREAST NEOPLASMS; CHEMISTRY; HUMAN; LUMINESCENCE; MAMMARY NEOPLASMS, EXPERIMENTAL; PATHOLOGY; RADIOFREQUENCY RADIATION; SURVIVAL; TUMOR VOLUME;

ADJUVANTS, PHARMACEUTIC; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DOXORUBICIN; FEMALE; HUMANS; LUMINESCENCE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; NANOPARTICLES; POLYETHYLENE GLYCOLS; RADIO WAVES; SURVIVAL ANALYSIS; TUMOR BURDEN;

EID: 84902144985     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-013-1102-8     Document Type: Article

References (33)

1. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer. 2005;5:161-71.
2. Lasic DD. Doxorubicin in sterically stabilized liposomes. Nature. 1996;380:561-2.
3. Dreher MR, Liu W, Michelich CR, Dewhirst MW, Yuan F, Chilkoti A. Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J Nat Cancer Inst. 2006;98:335-44.
4. Yuan F. Transvascular drug delivery in solid tumors. Semin Radiat Oncol. 1998;8:164-75.
5. Laginha KM, Verwoert S, Charrois GJ, Allen TM. Determination of doxorubicin levels in whole tumor and tumor nuclei in murine breast cancer tumors. Clin Cancer Res. 2005;11:6944-9.
6. Gabizon A, Goren D, Horowitz AT, Tzemach D, Lossos A, Siegal T. Long-circulating liposomes for drug delivery in cancer therapy: a review of biodistribution studies in tumor-bearing animals. Adv Drug Deliv Rev. 1997;24:337-44.
7. Peiris PM, Bauer L, Toy R, Tran E, Pansky J, Doolittle E, et al. Enhanced delivery of chemotherapy to tumors using a multicomponent nanochain with radio-frequency-tunable drug release. ACS Nano. 2012;6:4157-68.
8. Peiris PM, Toy R, Doolittle E, Pansky J, Abramowski A, Tam M, et al. Imaging metastasis using an integrin-targeting chain-shaped nanoparticle. ACS Nano. 2012;6:8783-95.
9. Peiris PM, Schmidt E, Calabrese M, Karathanasis E. Assembly of linear nano-chains from iron oxide nanospheres with asymmetric surface chemistry. PLoS One. 2011;6:e15927.
10. Park JH, von Maltzahn G, Zhang LL, Schwartz MP, Ruoslahti E, Bhatia SN, et al. Magnetic iron oxide nanoworms for tumor targeting and imaging. Adv Mater. 2008;20:1630-5.
11. Gossuin Y, Disch S, Vuong QL, Gillis P, Hermann RP, Park JH, et al. NMR relaxation and magnetic properties of superparamagnetic nanoworms. Contrast Media Mol Imaging. 2010. doi: 10.1002/cmmi.387.
12. Lu J, Ma S, Sun J, Xia C, Liu C, Wang Z, et al. Manganese ferrite nanoparticle micellar nanocomposites as MRI contrast agent for liver imaging. Biomaterials. 2009;30:2919-28.
13. Ai H, Flask C, Weinberg B, Shuai X, Pagel MD, Farrel D, et al. Magnetite-loaded polymeric micelles as ultrasensitive magnetic-resonance probes. Adv Mater. 2005;17:1949-52.
14. Buzdar AU. Preoperative chemotherapy treatment of breast cancer - a review. Cancer. 2007;110:2394-407.
15. Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr. 2001;30:96-102.
16. Tao K, Fang M, Alroy J, Sahagian GG. Imagable 4T1 model for the study of late stage breast cancer. BMC Cancer. 2008;8:228.
17. Dykxhoorn DM, Wu Y, Xie H, Yu F, Lal A, Petrocca F, et al. miR-200 enhances mouse breast cancer cell colonization to form distant metastases. PLoS One. 2009;4:e7181.
18. Yori JL, Seachrist DD, Johnson E, Lozada KL, Abdul-Karim FW, Chodosh LA, et al. Kruppel-like factor 4 inhibits tumorigenic progression and metastasis in a mouse model of breast cancer. Neoplasia. 2011;13:601-10.
19. Bolotin E, Cohen R, Bar L, Emanuel N, Ninio S, Lasic D, et al. Ammonium sulfate gradients for efficient and stable remote loading of amphipathic weak bases into liposomes and ligandoliposomes. J Liposome Res. 1994;4:455-79.
20. Lelekakis M, Moseley JM, Martin TJ, Hards D, Williams E, Ho P, et al. A novel orthotopic model of breast cancer metastasis to bone. Clin Exp Metastasis. 1999;17:163-70.
21. Aslaksonand CJ, Miller FR. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res. 1992;52:1399-405.
22. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747-52.
23. Bertucci F, Finetti P, Birnbaum D. Basal breast cancer: a complex and deadly molecular subtype. Curr Mol Med. 2012;12:96-110.
24. Perreard L, Fan C, Quackenbush JF, Mullins M, Gauthier NP, Nelson E, et al. Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay. Breast Cancer Res. 2006;8:R23.
25. Bertucci F, Finetti P, Cervera N, Charafe-Jauffret E, Buttarelli M, Jacquemier J, et al. How different are luminal A and basal breast cancers? Int J Cancer. 2009;124:1338-48.
26. Taketo MM. Reflections on the spread of metastasis to cancer prevention. Cancer Prev Res. 2011;4:324-8.
27. Gao ZG, Tian L, Hu J, Park IS, Bae YH. Prevention of metastasis in a 4T1 murine breast cancer model by doxorubicin carried by folate conjugated pH sensitive polymeric micelles. J Control Release. 2011;152:84-9.
28. Wang Z, Yu Y, Dai W, Lu J, Cui J, Wu H, et al. The use of a tumor metastasis targeting peptide to deliver doxorubicin-containing liposomes to highly metastatic cancer. Biomaterials. 2012;33:8451-60.
29. Pulaskiand BA, Ostrand-Rosenberg S. Mouse 4T1 breast tumor model. Curr Protoc Immunol. 2001 Chapter 20:Unit 20 22.
30. Gao ZG, Tian L, Hu J, Park IS, Bae YH. Prevention of metastasis in a 4T1 murine breast cancer model by doxorubicin carried by folate conjugated pH sensitive polymeric micelles. J Control Release. 2011;152:84-89.
31. Wendt MK, Molter J, Flask CA, Schiemann WP. In vivo dual substrate bioluminescent imaging. J Vis Exp. 2011;56:3245.
32. Yori JL, Seachrist DD, Johnson E, Lozada KL, Abdul-Karim FW, Chodosh LA, et al. Kruppel-like factor 4 inhibits tumorigenic progression and metastasis in a mouse model of breast cancer. Neoplasia. 2011;13:601-610.
33. Rose PG. Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer. Oncologist. 2005;10:205-14.